From the beginning, we have kept neonatal patients close to our hearts, and Masimo remains dedicated to improving their care through industry-leading solutions designed to ensure that even the youngest patients have bright futures.
Masimo’s breakthrough technology, Signal Extraction Technology® (SET®), overcame the limitations of conventional pulse oximetry with the ability to measure through motion and low perfusion. Masimo SET® is able to recognise that both arterial and venous blood can move, using parallel signal processing engines to separate the true arterial signal from sources of noise, including the venous signal. Two separate studies found that Masimo SET® pulse oximeters detected approximately 10 times more true events than other “Next Generation” pulse oximeters studied.1,2 Additionally, in another study comparing the ability of three pulse oximetry technologies to detect hypoxic events, Masimo SET® pulse oximetry demonstrated the highest sensitivity and specificity during induced conditions of motion and low perfusion.3
Masimo SET® had 3% missed true alarms and 5% false alarms versus 43% and 28%, respectively, using competitor technology.
Results shown are calculated by combining sensitivity and specificity outcomes of machine-generated and volunteer-generated motion.
Premature infants in neonatal intensive care units are routinely administered supplemental oxygen to help preserve vital organ function. However, too much oxygen administration, which can lead to hyperoxia, can increase the risk of severe eye damage from retinopathy of prematurity (ROP).4 Clinicians use pulse oximetry to help manage the administration of oxygen, but unreliable pulse oximetry measurements can result in over administration of oxygen and subsequent ROP.
In two NICU settings, Masimo SET® Measure-through Motion and Low Perfusion pulse oximetry, coupled with changes in clinical practice, showed significantly reduced rates of severe retinopathy of prematurity (ROP) and decreased the need for laser treatment to 0%.5,6
In a study of 571 inborn infants (<1250 g), a change in clinical practice combined with the use of Masimo SET® pulse oximetry, but not without it, led to significant reductions in severe ROP and need for laser therapy.5
In another study, following the implementation of Masimo SET® with a new protocol in a single tertiary neonatal center at Cedars-Sinai Medical Center (CSMC), the incidence of severe ROP decreased over a five-year period from 12.5% to 2.5% in very low birth weight infants.6
Methaemoglobinemia is a blood disorder characterised by an abnormal amount of methaemoglobin – a form of haemoglobin unable to effectively bind to oxygen – in the blood. Many drugs commonly used in hospitals — such as lidocaine, benzocaine, dapsone, and nitrates — may cause a dangerous reaction known as acquired methaemoglobinemia.7 Inhaled nitric oxide (iNO) therapy, and even topical anesthetics containing benzocaine or prilocaine, can cause elevated levels of methaemoglobin in neonates and infants.8,9
Masimo Pulse CO-Oximetry provides a method of noninvasively and continuously measuring methaemoglobin, SpMet®. Real-time SpMet monitoring may help clinicians intervene quickly and appropriately in cases involving elevated methaemoglobin levels.10
Masimo provides multiple sensor options to address the challenging needs and specific requirements of neonatal patients, including SofTouch sensors with little-to-no adhesive, which allow for gentle application on the skin of fragile newborn and pre-term babies, and the NeoPt-500, a non-adhesive sensor made specifically for newborns weighing 1 kg or less.
Masimo Blue Sensors are designed for use on cyanotic neonatal, infant, and paediatric patients with congenital heart disease and oxygen saturation as low as 60%.
Masimo offers a portfolio of sidestream capnography solutions to meet the challenges of ventilation monitoring in the NICU. Sidestream CO2 monitoring works with a full family of NomoLine™ sampling lines, airway adapter sets, and cannulas for use in a variety of clinical scenarios, including intubated and non-intubated patients in both low and high humidity applications. NomoLine technology is designed for low-flow applications, with a very low sampling rate of 50 ml/min, supporting use on patients with low tidal volumes and high breath rates, common characteristics of neonatal patients. Masimo capnography seamlessly integrates with Masimo SET® pulse oximetry and other key physiologic parameters, providing clinicians with greater visibility to a patient’s oxygenation, ventilation, and respiratory status.
Hay WW. Reliability of conventional and new oximetry in neonatal patients. J of Perinatol, 2002;22:360-36.
Barker SJ. "Motion-Resistant" Pulse Oximetry: A comparison of new and old models. Anesth Analg. 2002;95(4):967-72.
Shah et al. J Clin Anesth. 2012;24(5):385-91.
Saugstad et al. Journal of Perinatal Medicine. May 2006.
Castillo et al. Prevention of retinopathy of prematurity in preterm infants through changes in clinical practice and SpO2 Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
Chow et al. Can changes in clinical practice decrease the incidence of sever retinopathy of prematurity in very low birth weight infants? Pediatrics. 2003;111(2):339-345.
Ash-Bernal R et al. Medicine (Baltimore). 2004 Sep. 83(5):265-73.
Riou Y et al. Pediatric Research (1998) 43, 295-295.
U.S. Food & Drug, Consumer Updates, Benzocaine and Babies: Not a Good Mix.
Annabi EH et al. Anesth Analg. 2009 Mar;108(3):898-9.
* The use of the trademark PATIENT SAFETYNET is under license from University Health System Consortium.
Rad-97 with NomoLine capnography is not licensed for sale in Canada.
SpMet monitoring is not intended to replace laboratory blood testing. Blood samples should be analysed by laboratory instruments prior to clinical decision making.
For professional use. See instructions for use for full prescribing information, including indications, contraindications, warnings, and precautions.